It's been a horrible year for AVEO Pharmaceuticals (AVEO),
and arguably a lot of the damage has been self-inflicted. Others have
written at length about the FDA's decision to reject the company's
application for tivozanib in renal cell carcinoma(RCC),
as well as the deficiencies in the design of the pivotal trial, the
company's apparent tone-deafness towards the FDA, and the lack of
disclosure to shareholders regarding interactions with the agency.
I'm
not here to rehash all of that. For better or worse, tivozanib is
effectively dead in RCC for the time being. What I am interested in
doing, though, is trying to approach the company with as close to a
clean slate and fresh eyes as I can. After all, tivozanib is still in
two other Phase II studies and AVEO could certainly follow in the tracks
of other biotechs who faced crushing rejections only to come back later
with approvable drugs or indications.
Please read the full article here:
Looking At AVEO With Fresh Eyes
No comments:
Post a Comment